Drugs / FS-207
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07593144 | May 2026 → Jan 2029 expected | cancer | Foresight Therapeutics (Hefei) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FS-207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07593144 ↗ |
| Action | Inhibit | “FS-207 is designed to inhibit WRN.” NCT07593144 ↗ |
| Route | Oral | “FS-207 will be administered orally” NCT07593144 ↗ |
| Target | WRN | “FS-207 is designed to inhibit WRN.” NCT07593144 ↗ |